Skip to main content
. 2010 May 10;28(17):2817–2823. doi: 10.1200/JCO.2009.26.3988

Table 2.

Efficacy of Cediranib in Recurrent Glioblastoma

Radiographic Response Cediranib (AZD2171)
Wong et al20
No. % No. %
Volumetric criteria
    Partial 17/30 56.7 NA
    Minor 6/30 20.0
Macdonald criteria
    Partial 8/30 26.6 NA
    APF6 (%) 31 25.8 15
        95% CI 14.7 to 46.9
    PFS, days 117 (N = 31) 63
        95% CI 82 to 145
    OS, days 227 (N = 31) 175
        95% CI 177 to 293

Abbreviations: NA, not applicable; APF6, alive and progression free at 6 months; PFS, progression-free survival; OS, overall survival.